Good News about Novartis’ Cosentyx® for Psoriatic Arthritis
Novartis (NVS) has good news for Cosentyx®. Data emerging out 0f the FUTURE 5 clinical trial on patients with psoriatic arthritis (PsA) showed that there was no radiographic progression in around 90% of PsA patients who were treated with Cosentyx® (secukinumab) 300 mg, over 2 years. These data are being presented at the Annual European Congress of Rheumatology (EULAR) on 12-15, June, in Madrid, Spain.
Expert Quotes about Cosentyx®
Dr. Philip J. Mease, the Director of Rheumatology Research at the Swedish Medical Center/Providence St Joseph Health and Clinical Professor, University of Washington School of Medicine, Seattle, WA, explains, “Half of the patients with psoriatic arthritis experience bone erosion within approximately two years. Left untreated, this can lead to irreversible joint damage and disability, having a substantial impact on the quality of life. The availability of a treatment that is proven to inhibit the progression of PsA through two years gives physicians and patients more choice in the management of this debilitating condition.”
In addition to inhibition of radiographic progression of PsA the data demonstrate that: 89.5% (300mg), 82.3% (150mg) and 81.1% (150mg no loading dose [LD]) of patients treated with Cosentyx found no radiographic progression at 2 years.
Clinical responses, such as the American College of Rheumatology criteria (ACR20/50) and Psoriasis Area and Severity Index (PASI 90/100) were also maintained through 2 years. The data demonstrate that 77% of Cosentyx 300mg patients achieved ACR20, 51.9% ACR50, 70.1% PASI 90 and 49.5% PASI 100.
These results were also achieved at the lowest dose of Cosentyx, 150mg.
Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology said. Among other things, ” These data further reinforce Cosentyx as a comprehensive treatment that’s backed by over 100 studies, including five-year data across psoriasis, psoriatic arthritis and ankylosing spondylitis.”
About Psoriatic Arthritis
PsA is a complex disease with multiple symptoms. The disease is said to affect up to 50 million people worldwide and is part of a family of long-term inflammatory diseases (spondyloarthritis) that target the joints. If left untreated PsA patients can go on to develop irreversible radiographic structural damage. Radiographic damage is defined by joint inflammation, erosion and joint space narrowing; particularly in the hands and feet. PsA with radiographic progression is reported in more than half of patients.
PsA affects some people who have psoriasis. The majority of patients develop psoriasis first. However, the joint problems can begin before the skin lesions. The symptoms comprise joint pain, stiffness and swelling; including the fingertips and spine.
Like arthritis, PsA is a chronic disease that gets worse over time.
The PsA FUTURE 5 Clinical Trial
FUTURE 5 clinical trial is a Phase 3, randomized, double-blind, placebo-controlled study reporting on the effect of Cosentyx on radiographic progression across 2 years in PsA patients. In the study 996 adults with active PsA were randomized to receive subcutaneous Cosentyx 300 mg (with LD of 300 mg), 150 mg (LD 150 mg), 150 mg with no LD or placebo at baseline at Weeks 1, 2, 3, 4 and every 4 weeks thereafter. Patients could have the Cosentyx dose escalated from 150 to 300 mg, starting from Week 52, depending on physicians’ judgment.
More details about the trials are in the firm’s press release.
About Cosentyx®
Cosentyx is the first and only fully-human biologic that directly inhibits interleukin-17A (IL-17A) – cytokine involved in the inflammation and development of PsA, psoriasis (PsO), and ankylosing spondylitis (AS).
Cosentyx has shown long-lasting efficacy and a favorable safety profile while addressing psoriatic disease. It demonstrated sustained safety and long-lasting efficacy in three 5-year Phase III extension studies in PsO, PsA and AS. Since launch more than 200,000 patients worldwide have been treated with Cosentyx.
Prohost Observations
In the past couple of years Novartis has been working hard on upgrading its science, technologies and treatments. We are observing how Novartis is growing as a scientific institution with regard to improving the treatments of chronic inflammatory diseases, autoimmune diseases and cancer. One cannot miss the high quality and high degree efficacy in its newly approved products, lead products and other pipeline products. Recently, Novartis has put in the clinic the gene therapy Zolgensma® for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
We are expecting more approvals for Novartis products and high appreciation by investors in the drug sector.
To read more articles about this firm please run a search from our website by clicking here.
Novartis: Psoriatic Arthritis Patients on Cosentyx Had No Radiologic Progression After 2 Years of Treatment
Good News about Novartis’ Cosentyx® for Psoriatic Arthritis
Novartis (NVS) has good news for Cosentyx®. Data emerging out 0f the FUTURE 5 clinical trial on patients with psoriatic arthritis (PsA) showed that there was no radiographic progression in around 90% of PsA patients who were treated with Cosentyx® (secukinumab) 300 mg, over 2 years. These data are being presented at the Annual European Congress of Rheumatology (EULAR) on 12-15, June, in Madrid, Spain.
Expert Quotes about Cosentyx®
Dr. Philip J. Mease, the Director of Rheumatology Research at the Swedish Medical Center/Providence St Joseph Health and Clinical Professor, University of Washington School of Medicine, Seattle, WA, explains, “Half of the patients with psoriatic arthritis experience bone erosion within approximately two years. Left untreated, this can lead to irreversible joint damage and disability, having a substantial impact on the quality of life. The availability of a treatment that is proven to inhibit the progression of PsA through two years gives physicians and patients more choice in the management of this debilitating condition.”
In addition to inhibition of radiographic progression of PsA the data demonstrate that: 89.5% (300mg), 82.3% (150mg) and 81.1% (150mg no loading dose [LD]) of patients treated with Cosentyx found no radiographic progression at 2 years.
Clinical responses, such as the American College of Rheumatology criteria (ACR20/50) and Psoriasis Area and Severity Index (PASI 90/100) were also maintained through 2 years. The data demonstrate that 77% of Cosentyx 300mg patients achieved ACR20, 51.9% ACR50, 70.1% PASI 90 and 49.5% PASI 100.
These results were also achieved at the lowest dose of Cosentyx, 150mg.
Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology said. Among other things, ” These data further reinforce Cosentyx as a comprehensive treatment that’s backed by over 100 studies, including five-year data across psoriasis, psoriatic arthritis and ankylosing spondylitis.”
About Psoriatic Arthritis
PsA is a complex disease with multiple symptoms. The disease is said to affect up to 50 million people worldwide and is part of a family of long-term inflammatory diseases (spondyloarthritis) that target the joints. If left untreated PsA patients can go on to develop irreversible radiographic structural damage. Radiographic damage is defined by joint inflammation, erosion and joint space narrowing; particularly in the hands and feet. PsA with radiographic progression is reported in more than half of patients.
PsA affects some people who have psoriasis. The majority of patients develop psoriasis first. However, the joint problems can begin before the skin lesions. The symptoms comprise joint pain, stiffness and swelling; including the fingertips and spine.
Like arthritis, PsA is a chronic disease that gets worse over time.
The PsA FUTURE 5 Clinical Trial
FUTURE 5 clinical trial is a Phase 3, randomized, double-blind, placebo-controlled study reporting on the effect of Cosentyx on radiographic progression across 2 years in PsA patients. In the study 996 adults with active PsA were randomized to receive subcutaneous Cosentyx 300 mg (with LD of 300 mg), 150 mg (LD 150 mg), 150 mg with no LD or placebo at baseline at Weeks 1, 2, 3, 4 and every 4 weeks thereafter. Patients could have the Cosentyx dose escalated from 150 to 300 mg, starting from Week 52, depending on physicians’ judgment.
More details about the trials are in the firm’s press release.
About Cosentyx®
Cosentyx is the first and only fully-human biologic that directly inhibits interleukin-17A (IL-17A) – cytokine involved in the inflammation and development of PsA, psoriasis (PsO), and ankylosing spondylitis (AS).
Cosentyx has shown long-lasting efficacy and a favorable safety profile while addressing psoriatic disease. It demonstrated sustained safety and long-lasting efficacy in three 5-year Phase III extension studies in PsO, PsA and AS. Since launch more than 200,000 patients worldwide have been treated with Cosentyx.
Prohost Observations
In the past couple of years Novartis has been working hard on upgrading its science, technologies and treatments. We are observing how Novartis is growing as a scientific institution with regard to improving the treatments of chronic inflammatory diseases, autoimmune diseases and cancer. One cannot miss the high quality and high degree efficacy in its newly approved products, lead products and other pipeline products. Recently, Novartis has put in the clinic the gene therapy Zolgensma® for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
We are expecting more approvals for Novartis products and high appreciation by investors in the drug sector.
To read more articles about this firm please run a search from our website by clicking here.
Other Articles